Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on October 1, 2024. These awards consist of non-qualified share options to purchase a total of 47,600 ordinary shares. The options were granted under the company's 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price of $22.63 per share, which was Bicycle Therapeutics' closing trading price on September 30, 2024. The options will vest over four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato la concessione di premi di incentivo a otto nuovi dipendenti il 1 ottobre 2024. Questi premi consistono in opzioni per l'acquisto di azioni non qualificate che consentono l'acquisto di un totale di 47.600 azioni ordinarie. Le opzioni sono state concesse nell'ambito del Piano di Incentivo 2024 dell'azienda e approvate dal Comitato Compensi in conformità con il Regolamento di Quotazione Nasdaq 5635(c)(4).
Ogni opzione ha un prezzo di esercizio di $22,63 per azione, che corrisponde al prezzo di chiusura di Bicycle Therapeutics del 30 settembre 2024. Le opzioni matureranno in quattro anni, con il 25% che matura al primo anniversario della data di inizio della maturazione e il restante 75% che matura mensilmente nei successivi 36 mesi, a condizione di continuare a lavorare.
Bicycle Therapeutics (NASDAQ: BCYC) ha anunciado la concesión de premios de inducción a ocho nuevos empleados el 1 de octubre de 2024. Estos premios consisten en opciones de acciones no calificadas para adquirir un total de 47,600 acciones ordinarias. Las opciones fueron otorgadas bajo el Plan de Inducción 2024 de la empresa y aprobadas por el Comité de Compensación de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4).
Cada opción tiene un precio de ejercicio de $22.63 por acción, que fue el precio de cierre de Bicycle Therapeutics el 30 de septiembre de 2024. Las opciones se consolidarán durante cuatro años, con un 25% consolidándose en el primer aniversario de la fecha de inicio de la consolidación y el 75% restante consolidándose mensualmente durante los siguientes 36 meses, sujeto a la continuación del empleo.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 2024년 10월 1일에 8명의 신규 직원에게 유인 보상을 부여했다고 발표했습니다. 이러한 보상은 총 47,600주 일반주식을 매입할 수 있는 비자격 주식 옵션으로 구성됩니다. 이 옵션은 회사의 2024 유인 계획에 따라 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 보상 위원회에서 승인되었습니다.
각 옵션의 행사 가격은 주당 $22.63이며, 이는 2024년 9월 30일의 바이시클 테라퓨틱스의 종가입니다. 옵션은 4년 동안 분할 지급됩니다, 첫 해 기념일에 25%가 분할 지급되며, 나머지 75%는 다음 36개월 동안 월별로 분할 지급됩니다. 이는 지속적인 고용을 조건으로 합니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé la concession de primes d'incitation à huit nouveaux employés le 1er octobre 2024. Ces primes se composent d'options d'achat d'actions non qualifiées permettant d'acheter un total de 47 600 actions ordinaires. Les options ont été accordées dans le cadre du Plan d'incitation 2024 de l'entreprise et approuvées par le Comité de Rémunération conformément à la Règle d'inscription Nasdaq 5635(c)(4).
Chaque option a un prix d'exercice de 22,63 $ par action, correspondant au prix de clôture de Bicycle Therapeutics au 30 septembre 2024. Les options seront acquises sur quatre ans, avec 25 % acquises au premier anniversaire de la date de début de l'acquisition et les 75 % restants acquises mensuellement au cours des 36 mois suivants, sous réserve d'une continuité d'emploi.
Bicycle Therapeutics (NASDAQ: BCYC) hat am 1. Oktober 2024 die Gewährung von Anreizprämien an acht neue Mitarbeiter bekannt gegeben. Diese Prämien bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von insgesamt 47.600 Stammaktien. Die Optionen wurden im Rahmen des 2024 Anreizplans des Unternehmens gewährt und vom Vergütungsausschuss gemäß Nasdaq-Listungsregel 5635(c)(4) genehmigt.
Jede Option hat einen Ausübungspreis von $22.63 pro Aktie, was dem Schlusskurs von Bicycle Therapeutics am 30. September 2024 entspricht. Die Optionen reifen über vier Jahre, wobei 25% am ersten Jahrestag des Beginns der Reifung und die verbleibenden 75% monatlich über die folgenden 36 Monate reifen, unter der Voraussetzung einer fortgesetzten Beschäftigung.
- Granted inducement awards to attract new talent
- Aligning employee interests with shareholders through share options
- Potential dilution of existing shareholders' equity
Each option has an exercise price equal to
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241002362023/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
How many new employees received inducement awards from Bicycle Therapeutics (BCYC) on October 1, 2024?
What is the exercise price of the share options granted by Bicycle Therapeutics (BCYC) on October 1, 2024?
How many ordinary shares can be purchased with the non-qualified share options granted by Bicycle Therapeutics (BCYC)?
What is the vesting schedule for the share options granted by Bicycle Therapeutics (BCYC) on October 1, 2024?
